Imsidolimab ( DrugBank: Imsidolimab )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
37膿疱性乾癬(汎発型)7

37. 膿疱性乾癬(汎発型)


臨床試験数 : 79 薬物数 : 57 - (DrugBank : 21) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 102
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05366855
(ClinicalTrials.gov)
April 21, 202225/4/2022Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular PsoriasisA Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular PsoriasisGeneralized Pustular PsoriasisBiological: Imsidolimab;Other: PlaceboAnaptysBio, Inc.NULLRecruiting18 Years80 YearsAll45Phase 3United States;Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Morocco;Poland;Romania;Spain;Taiwan;Thailand;Tunisia;Turkey
2NCT05352893
(ClinicalTrials.gov)
April 14, 202225/4/2022Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPPA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular PsoriasisGeneralized Pustular PsoriasisDrug: Imsidolimab high dose;Drug: Imsidolimab low dose;Other: PlaceboAnaptysBio, Inc.NULLRecruiting18 Years80 YearsAll45Phase 3United States;Australia;Georgia;Germany;Korea, Republic of;Malaysia;Morocco;Poland;Romania;Slovakia;Spain;Taiwan;Thailand;Tunisia;Turkey
3EUCTR2021-001447-27-ES
(EUCTR)
07/02/202212/11/2021A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular PsoriasisA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis - Efficacy and Safety of Imsidolimab in Subjects with Generalized Pustular Psoriasis Subjects with generalized pustular psoriasis
MedDRA version: 20.0;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Code: ANB019
INN or Proposed INN: anti-IL-36R monoclonal antibody
AnaptysBio Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
45Phase 3Taiwan;Thailand;Malaysia;Spain;Australia;Georgia;Germany;Korea, Republic of
4EUCTR2021-001448-90-FR
(EUCTR)
02/02/202205/10/2021A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular PsoriasisA Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis - Long-Term Safety and Efficacy of Imsidolimab in Subjects with Generalized Pustular Psoriasis Subjects with generalized pustular psoriasis
MedDRA version: 20.0;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Code: ANB019
INN or Proposed INN: anti-IL-36R monoclonal antibody
AnaptysBio Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
45Phase 3France;Taiwan;Spain;Malaysia;Thailand;Australia;Georgia;Germany;Korea, Republic of
5EUCTR2021-001448-90-ES
(EUCTR)
21/01/202219/10/2021A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular PsoriasisA Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis - Long-Term Safety and Efficacy of Imsidolimab in Subjects with Generalized Pustular Psoriasis Subjects with generalized pustular psoriasis
MedDRA version: 20.0;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Code: ANB019
INN or Proposed INN: anti-IL-36R monoclonal antibody
AnaptysBio Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
45Phase 3Taiwan;Thailand;Malaysia;Spain;Australia;Georgia;Germany;Korea, Republic of
6EUCTR2021-001448-90-DE
(EUCTR)
08/12/202108/09/2021A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular PsoriasisA Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis - Long-Term Safety and Efficacy of Imsidolimab in Subjects with Generalized Pustular Psoriasis Subjects with generalized pustular psoriasis
MedDRA version: 20.0;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Code: ANB019
INN or Proposed INN: anti-IL-36R monoclonal antibody
Product Code: ANB019
INN or Proposed INN: anti-IL-36R monoclonal antibody
AnaptysBio Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
45Phase 3United States;Taiwan;Spain;Thailand;United Kingdom;France;Malaysia;Poland;Romania;Australia;Georgia;Germany;Korea, Republic of
7EUCTR2021-001447-27-DE
(EUCTR)
08/12/202108/09/2021A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular PsoriasisA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis - Efficacy and Safety of Imsidolimab in Subjects with Generalized Pustular Psoriasis Subjects with generalized pustular psoriasis
MedDRA version: 20.0;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Code: ANB019
INN or Proposed INN: anti-IL-36R monoclonal antibody
Product Code: ANB019
INN or Proposed INN: anti-IL-36R monoclonal antibody
AnaptysBio Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
45Phase 3Georgia;Germany;United States;Taiwan;Spain;Thailand;United Kingdom;France;Malaysia;Poland;Romania;Australia;Korea, Republic of